Elizabeth Traxler, MD, Ph.D.

Liz Traxler, MD, PhD, is a physician scientist and fellow in hematology/oncology at the Hospital at University of Pennsylvania, where her clinical and research interests focus on patients with classical hematology disorders. She pursued her MD/PhD training at the Perelman School of Medicine, completing her graduate thesis work in Dr. Mitchell Weiss’s laboratory. Her work centered on red blood cell development and novel therapies for sickle cell disease and thalassemia using genome editing.

During hematology fellowship, she joined Dr. Gerd Blobel’s lab at Children’s Hospital of Philadelphia for her post-doctoral research, where her work builds on her graduate studies on hemoglobinopathies. Her research focuses on using a customized genome scale CRISPR screening platform to identify novel regulators of fetal hemoglobin, with the aim to pinpoint pathways for drug candidates. She received recognition through the American Society of Hematology Research Training Award for Fellows, and the Penn Measey Scholars in Molecular Medicine in 2023. In the long-term as a physician scientist, she envisions an independent research program at the nexus of classical hematology, genetics, and developmental biology.

Selected Publications

Traxler EA, Hexner EO. Running interferon interference in treating PV/ET: meeting unmet needs. Hematology Am Soc Hematol Educ Program 2021 Dec;2021(1):463-468.

Ji, X, Jha A, Humenik J, Ghanem LR, Kromer A, Duncan-Lewis C, Traxler E, Weiss MJ, Barash Y, Liebhaber SA. RNA-binding proteins PCBP1 and PCBP2 are critical determinants of murine erythropoiesis. Mol Cell Biol 2021 Aug;41(9):e0066820.

Halaby R, Cuker A, Yui J, Matthews A, Ishaaya E, Traxler E, Domenico C, Cooper T, Tierney A, Niami P, van der Rijst N, Adusumalli S, Gutsche J, Giri J, Pugliese S, Hecht THE, Pishko AM. Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: a retrospective cohort study. J Thromb Haemost 2021 Jun;19(6)1533-1545.

Traxler EA, Thom CS, Yao Y, Paralkar V, Weiss MJ. Nonspecific inhibition of erythropoiesis by short hairpin RNAs. Blood 2018 Jun;131(24):2733-2736.

Traxler EA*, Yao Y*, Wang YD, Woodard KJ, Kurita R, Nakamura Y, Hughes JR, Hardison RC, Blobel GA, Li C, Weiss MJ. A genome-editing strategy to treat b-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nature Medicine 2016 Sep;22(9):987-990. *authors contributed equally

Bui HM, Enis D, Robcuic MR, Nurmi HJ, Cohen J, Chen M, Yang Y, Dhillon V, Johnson K, Zhang H, Kirkpatrick R, Traxler E, Anisimov A, Alitalo K, Kahn ML. Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. Journal of Clinical Investigation 2016 Jun;126(6):2167- 2180.

Ghanem LR, Kromer A, Silverman IM, Chatterji P, Traxler E, Penzo-Medez A, Weiss MJ, Stanger BZ, Liebhaber SA. The Poly(c) binding protein Pcbp2 and its retrotransposed derivative Pcbp1 are independently essential to mouse development. Molecular Cell Biology 2015 Nov;36(2):304-319.

Thom CS*, Traxler EA*, Khandros E, Nickas JM, Zhou OY, Lazarus JE, Silva APG, Prabhu D, Yao Y, Mackay JP, Holzbaur ELF, Weiss MJ. Trim58 degrades dynein and regulates terminal erythropoiesis. Developmental Cell 2014 Sep;30(6):688-700. *authors contributed equally

Traxler E, Weiss MJ. Congenital dyserythropoietic anemias: III’s a charm. Blood 2013 June;121(23):4614-5.


Email: Elizabeth.Traxler2@pennmedicine.upenn.edu